The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Long-Term Benefits, Risks of Biologic Disease-Modifying Anti-Rheumatic Drugs in Patients with RA

Long-Term Benefits, Risks of Biologic Disease-Modifying Anti-Rheumatic Drugs in Patients with RA

December 19, 2017 • By Nan Yang, PharmD, & Kurt Oelke, MD, on behalf of the ARHP Practice Committee

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Green Apple / shutterstock.com

Green Apple / shutterstock.com

Two decades have passed since the first biologic disease-modifying anti-rheumatic drug (bDMARD) was approved. Studies on the long-term use of biologics in different disease states, such as for cardiovascular disease (CVD) and malignancy, as well as for knee/hip replacement, reveal some encouraging news.

You Might Also Like
  • Cardiovascular Disease Rate Differs Between SLE Patients of Different Races, Ethnicities
  • Disease-Modifying Antirheumatic Drugs Cut RA Risk
  • Long-Term Antibiotic Treatment for Lyme Disease Shows No Benefits
Explore This Issue
December 2017

In clinical trials, bDMARDs have been shown to increase the risk of infection and malignancy, but they are also known for better liver and kidney tolerance among patients with rheumatoid arthritis (RA) than synthetic DMARDs (sDMARDs). bDMARDs also have significant clinical benefits over sDMARDs when controlling moderate to severe autoimmune diseases caused by uncontrolled chronic inflammation, such as rheumatoid arthritis (RA), psoriasis, psoriatic arthritis and polymyalgia rheumatica, but heretofore evidence is lacking that they reduce comorbidities in RA. The most common comorbidities among RA patients are CVD and joint damage.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

A systematic literature review, which informed the 2016 update of the EULAR recommendations for RA management, studied the safety and efficacy of synthetic and biologic DMARDs in RA patients and showed that bDMARDs have favorable effects on CV events and total knee/hip replacement.1

It’s worthwhile to review the long-term benefits and risks of biologics among RA patients and other chronic systemic inflammatory patient populations.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Per one study conducted in Sweden, total joint replacement surgeries are increasing in general, while the number of TKR & THR surgeries is decreasing in patients with a primary RA diagnosis. Introduction of biologics in RA patients may be an important contributing factor.

Benefits in Total Knee & Hip Replacements

Considering quality of life, one of the largest burdens for RA patients is total knee or hip replacement (TKR or THR) due to chronic joint damage. TKR and THR have increased in the general patient population with the aging of baby boomers. Prior to the introduction of biologics for RA patients, 25% of these patients would require TKR or THR within 10 years.2 Per one study conducted in Sweden, total joint replacement surgeries are increasing in general, while the number of TKR and THR surgeries is decreasing in patients with a primary RA diagnosis.3 Introduction of biologics in RA patients may be an important contributing factor.

In 2014 in the U.S., researchers used data from the Nationwide Inpatient Sample, Health Care Cost and Utilization Project in a study that focused on the first three tumor necrosis factor (TNF) inhibitors: etanercept, infliximab and adalimumab (FDA approved in 1998, 1999 and 2002, respectively).4 In this study, patients were categorized into three subgroups: 1) RA as primary diagnosis, 2) RA as secondary diagnosis and 3) no RA. With a few exceptions, only the group of patients with RA as primary diagnosis were shown to have experienced an overall 32% and 24% reduction in TKR and THR surgeries, respectively, since 1993, and consistent decreasing rates after 2002.4

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: Association of Rheumatology Professionals (ARP), bDMARD, benefit, biologic disease modifying anti-rheumatic drug, Cardiovascular disease, Clinical, hip, knee, outcome, patient care, replacement, Research, Rheumatoid arthritis, rheumatologist, rheumatology, risk, study, therapyIssue: December 2017

You Might Also Like:
  • Cardiovascular Disease Rate Differs Between SLE Patients of Different Races, Ethnicities
  • Disease-Modifying Antirheumatic Drugs Cut RA Risk
  • Long-Term Antibiotic Treatment for Lyme Disease Shows No Benefits
  • Knee Replacement Offers Cardiovascular Benefits for Patients with Arthritis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)